What is the typical semaglutide dose?
Clinical semaglutide dose ranges span 0.25 mg starter doses (typical week 1-4 in titration protocols) through 2.4 mg per week maintenance doses for chronic weight management, with the 0.5-1 mg range typical for type 2 diabetes glycemic-control protocols. All clinical doses are administered subcutaneously once weekly.
What the research literature says
Semaglutide’s clinical dose range was characterised across the SUSTAIN program for type 2 diabetes (SUSTAIN 1, PMID 28110911), the STEP program for chronic weight management (STEP 1, PMID 33567185; STEP overview, PMID 32441473), and the SELECT cardiovascular-outcomes trial in obesity without diabetes (PMID 37952131). The typical clinical-protocol pattern: start at 0.25 mg once weekly for 4 weeks (titration tolerability), increase to 0.5 mg for the next 4 weeks, then continue increasing every 4 weeks to the target maintenance dose.
For type 2 diabetes the maintenance target is typically 0.5 mg or 1 mg per week. For chronic weight management the maintenance target is 2.4 mg per week. For cardiovascular-outcome reduction in patients without diabetes the SELECT trial used the 2.4 mg per week dose (PMID 37952131). Higher doses past 2.4 mg per week are not routinely used in clinical practice.
Research-supply protocols typically mirror the clinical dose-titration pattern unless the specific experimental question requires deviation. The Marso cardiovascular-outcomes trial in type 2 diabetes documented cardiovascular-safety at doses across the 0.5-1 mg per week range (PMID 27633186).
Why this matters in research context
The 4-week step-up titration pattern is the operational anchor across semaglutide protocols specifically because higher starting doses produce GI tolerability issues that limit research-protocol completion. Researchers running semaglutide protocols should adopt the clinical-pattern dose-titration cadence unless specific experimental design requires deviation — abrupt high-dose initiation typically produces dose-limiting GI effects within 1-2 weeks.
Related compounds
- Semaglutide 10mg — the compound covered by this answer
Related research questions
- What is the half-life of semaglutide?
- How much bacteriostatic water with semaglutide?
- How does semaglutide work?
References
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-1844. [PMID 27633186]
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260. [PMID 28110911]
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. [PMID 33567185]
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389(24):2221-2232. [PMID 37952131]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Semaglutide is sold strictly as a research-grade reagent for laboratory and bench research applications.